Ambit to Profile Additional Compounds for Bristol-Myers, GSK, Pfizer

Jan 17, 2005

NEW YORK, Jan. 17 (GenomeWeb News) - Ambit Biosciences will profile additional compounds for Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer using its kinase and screening technologies, the San Diego-based company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

French Funding Agency Head Resigns

The president of France's National Research Agency has resigned, according to Nature News.

Right to Try Versus Clinical Trials

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

This Week in PNAS

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

'Lifestyle Zone'

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.

Main menu